TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04213547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss frame sleep extension intervention
Description: Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
Study: NCT01071681

Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients under daily life treatment receiving Pritor according to local drug information.
Study: NCT00990106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin hydrochloride
Description: Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02138890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APS
Description: Intra-articular Injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intra-articular injection
Study: NCT03144739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in management of children's mental health problems
Description: General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current collaborative care protocol
Description: General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
Study: NCT02892994

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT01307826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: classical massage (Swedish massage)
Study: NCT03826940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 60 MG
Description: 60 MG Lovastatin per day for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 60 MG
Description: 60 MG Lovastatin per day for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 60 MG Placebo per day for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 60 MG Placebo per day for 3 consecutive days
Study: NCT00685165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone 50 mg Tablet
Description: 50 mg tablet administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone (Mysoline®) 50 mg Tablet
Description: 50 mg tablet administered after an overnight fast of at least 10 hours.
Study: NCT02545933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study: NCT03890185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo alone
Description: Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
Study: NCT02545933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Vorapaxar will be administered at the dose of 2.5mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Vorapaxar will be administered at the dose of 2.5mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin will be administered at the dose of 81mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin will be administered at the dose of 81mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study: NCT03417895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study: NCT03153696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit Intervention
Description: The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cellie Coping Kit Intervention
Description: The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
Study: NCT03495466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local only anesthesia vs Local with sedation anesthesia
Description: The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local only anesthesia vs Local with sedation anesthesia
Description: The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
Study: NCT02066766

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study: NCT02371824

Intervention type: OTHER
Intervention: MRI sequence
Description: One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
Study: NCT04340635

Intervention type: OTHER
Description: Without intervention
Study: NCT00955214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté paclitaxel-eluting coronary stent system
Description: diameter is 2.5mm
Study: NCT02326038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: single oral administration of 20 mg tablet
Study: NCT01859234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-bevacizumab
Description: 89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
Study: NCT03841110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT500
Description: FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT500
Description: FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT500
Description: FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immune Checkpoint Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immune Checkpoint Inhibitor
Study: NCT03417895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study: NCT02374892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAPTER III Study Intervention
Description: This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
Study: NCT00486629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and dietary education
Description: Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
Study: NCT03841110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune Checkpoint Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune Checkpoint Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Immune Checkpoint Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Immune Checkpoint Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT04535804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin/placebo
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Study: NCT03841110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study: NCT01677689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomivir®
Description: Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Study: NCT00649844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
Study: NCT03980015

Intervention type: OTHER
Intervention: antibiotic treatment
Description: Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
Study: NCT01601535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Description: Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously during each course on study day 1 through day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally during each course on study day 1 through day 5.
Study: NCT04535804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin/placebo
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Study: NCT03821753

Intervention type: OTHER
Intervention: Case
Description: * OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests

Intervention type: OTHER
Intervention: Control
Description: * OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests
Study: NCT02495324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks of placebo PO daily
Study: NCT02006953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus feeding schedule following gastrostomy tube placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous chimney feeds following gastrostomy tube placement
Study: NCT02495324

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 weeks of placebo PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 weeks of placebo PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan medoxomil
Description: 10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
Study: NCT03849313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases
Study: NCT03084796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Dose Response: Test one of four different doses of CHF 5259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Dose Response: Test one of four different doses of CHF 5259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Dose Response: Test one of four different doses of CHF 5259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Dose Response: Test one of four different doses of CHF 5259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide 18 µg Inhalation Capsule
Description: Active Control
Study: NCT04043117

Intervention type: OTHER
Intervention: Body Image evaluation
Description: Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves.

Intervention type: OTHER
Intervention: Self esteem evaluation
Description: Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false.
Study: NCT03651037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrivors+BH
Description: Digital health platform for breast cancer patients that measures adherence and engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrivors+BH
Description: Digital health platform for breast cancer patients that measures adherence and engagement.
Study: NCT02530346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Mechanical Bowel Preparation
Description: no enemas or oral laxatives will be given in this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed